ArticleCancer medicine2025
Financial Toxicity Among Cancer Patients in Slovenia.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Assessing Financial Toxicity in Cancer: A Global Systematic Review and Meta-Analysis Using an Asset Framework.Cancer medicine · 2026Pooled it
- Financial hardship in cancer family caregivers: a scoping review.BMC palliative care · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe ageing population, increasing medical costs and a number of newly diagnosed cancer cases among the working population are increasing the financial burden on healthcare systems. The extent of financial toxicity in Slovenian patients has been insufficiently researched, as has its impact on quality of life (QoL).
methodsTo evaluate financial toxicity, the Functional Assessment of Chronic Illness Therapy (COST-FACIT) questionnaire was translated into Slovenian, validated, introduced and compared with the European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30). Additional questions were incorporated into the questionnaire to further quantify and objectify financial toxicity. The study was cross-sectional. The statistical analysis was based on descriptive and inferential statistics and exploratory data analysis.
resultsOut of 590 analysed participants, financial toxicity was absent in 57.2% but present at mild to moderate levels in 42.8%. Key risk factors included lower income, age ≤ 65, employment, active oncologic treatment, rural residence and religious affiliation. Post hoc analyses showed higher financial toxicity in those with ≤ 600 EUR monthly income, employed patients and spiritual individuals, while cancer type showed no significant differences. The correlation between financial toxicity and QoL was mild. Objective measures of financial toxicity include direct costs (e.g., transportation, supplements and medical devices) and indirect costs (e.g., loss of income) associated with disease and treatment, which burdened more than 40% of the studied population.
conclusionsThe COST-FACIT proved to be a helpful screening tool for identifying patients at risk, even in a public healthcare system such as the Slovenian system. On average, financial toxicity is low due to the publicly funded financial system covering the treatment and rehabilitation of malignant diseases. The age structure of cancer patients and secure pension income further contribute to this outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.